Blocking RAS-RAF-MEK-ERK cell growth pathway that channelizes signals from upstream EGFR, KRAS, and BRAF [12–14] has been shown to be important in treating NSCLC. Here, MAP2K7 is linked to non-small cell lung carcinoma.